April 12, 2023
Press Releases
March 20, 2023
Panavance Therapeutics Announces Acceptance of Abstract to be Presented at
the American Association for Cancer Research (AACR) Annual Meeting 2023
January 5, 2023
Panavance Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
December 5, 2022
Panavance Therapeutics to Participate at the Virtual Investor Innovations in Oncology Spotlight Event
November 14, 2022
Panavance Therapeutics to Present at the Pharma Partnering US Summit 2022
November 2, 2022
Panavance Therapeutics to Present at BioFuture 2022
August 8, 2022
Panavance Therapeutics Announces Publication of Promising Preclinical Data Evaluating GP-2250 for the Treatment of Malignant Peritoneal Mesothelioma
June 28, 2022
Panavance Therapeutics Announces Orphan Drug Designation for GP-2250 for the Treatment of Pancreatic Cancer
June 9, 2022
Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Pancreatic Neuroendocrine Carcinoma
January 19, 2022